MwanzoEBS • NYSE
add
Emergent Biosolutions Inc
$ 5.49
Baada ya Saa za Kazi:(1.09%)-0.060
$ 5.43
Imefungwa: 25 Apr, 17:55:01 GMT -4 · USD · NYSE · Kanusho
Bei iliyotangulia
$ 5.37
Bei za siku
$ 5.30 - $ 5.70
Bei za mwaka
$ 1.82 - $ 15.10
Thamani ya kampuni katika soko
298.31M USD
Wastani wa hisa zilizouzwa
1.15M
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
NYSE
Habari za soko
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (USD) | Des 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 194.70M | -29.61% |
Matumizi ya uendeshaji wa biashara | 140.80M | -33.40% |
Mapato halisi | -31.30M | 36.77% |
Kiwango cha faida halisi | -16.08 | 10.17% |
Mapato kwa kila hisa | 0.05 | 106.49% |
EBITDA | 21.00M | 255.56% |
Asilimia ya kodi ya mapato | -13.41% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (USD) | Des 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 99.50M | -10.92% |
Jumla ya mali | 1.39B | -23.78% |
Jumla ya dhima | 906.90M | -22.74% |
Jumla ya hisa | 482.80M | — |
hisa zilizosalia | 54.34M | — |
Uwiano wa bei na thamani | 0.60 | — |
Faida inayotokana na mali | -0.75% | — |
Faida inayotokana mtaji | -0.92% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (USD) | Des 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -31.30M | 36.77% |
Pesa kutokana na shughuli | -79.90M | -348.91% |
Pesa kutokana na uwekezaji | 28.60M | 350.88% |
Pesa kutokana na ufadhili | elfu 500.00 | -89.36% |
Mabadiliko halisi ya pesa taslimu | -50.80M | -312.55% |
Mtiririko huru wa pesa | -5.54M | -113.72% |
Kuhusu
Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes.
Among the company's products are the controversial BioThrax, the only anthrax vaccine licensed by the U.S. Food and Drug Administration and Narcan for the emergency treatment of opioid overdose. The company also manufactures pharmaceuticals for infectious diseases like cholera and typhoid.
During the COVID-19 pandemic, Emergent BioSolutions also produced Johnson & Johnson/Janssen and Oxford–AstraZeneca vaccines at one of its plants; however, this was marked by contamination and other production issues, and millions of doses of vaccine had to be discarded. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
5 Sep 1998
Makao Makuu
Tovuti
Wafanyakazi
900
